DermatologyRegeneron
Regeneron Reports Five-Year LIBERTY AD SOLO Data for Dupixent in Atopic Dermatitis
BMI
Biotechnology Media Insights
Editorial Team · January 5, 2024
Regeneron and Sanofi present five-year follow-up data from LIBERTY AD SOLO trials showing sustained skin clearance with Dupixent in moderate-to-severe atopic dermatitis.
Regeneron and Sanofi today presented five-year follow-up data from the Phase 3 LIBERTY AD SOLO 1 and SOLO 2 trials evaluating Dupixent (dupilumab) in patients with moderate-to-severe atopic dermatitis. The data showed that the skin clearance benefits of Dupixent were maintained over five years of treatment.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.